Lamivudine Teva Pharma

Lamivudine, the active ingredient in Lamivudine Teva Pharma, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adult patients. GNH USA supplies Lamivudine Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral medication that targets viral replication in specific infections.

- HIV infection: reduces plasma HIV‑1 RNA levels and helps restore immune function. - Chronic hepatitis B infection: suppresses hepatitis B virus replication and improves liver enzyme profiles. - HIV‑1 infected patients receiving combination antiretroviral therapy: contributes to overall viral suppression as part of a multi‑drug regimen.

Lamivudine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional and usually transient. - Fatigue: persistent tiredness reported by some patients. - Diarrhea: loose stools without severe dehydration. - Insomnia: difficulty falling or staying asleep. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: buildup of lactic acid leading to metabolic disturbances. - Severe hepatotoxicity: marked elevation of liver enzymes or liver failure. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, fever, or eosinophilia. - Peripheral neuropathy: tingling or numbness in extremities.

When prescribing lamivudine, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline enzymes and follow periodically. - Renal function assessment: adjust dosing in patients with impaired clearance. - Hepatitis B flare vigilance: watch for reactivation when therapy is stopped. - Pregnancy considerations: evaluate risk‑benefit before use. - Concomitant medication review: avoid drugs that increase mitochondrial toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lamivudine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Didanosine: combined use raises risk of pancreatitis and peripheral neuropathy. - Stavudine: concurrent therapy can enhance mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may increase lamivudine plasma levels. - Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): may affect viral suppression dynamics. - Nephrotoxic agents (e.g., aminoglycosides): require renal function monitoring. - Alcohol: can exacerbate liver toxicity. - Herbal supplements (e.g., St. John’s wort): may alter drug metabolism.